Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 3/2011

01.06.2011

The Outbreak of Cryptococcus gattii in Western North America: Epidemiology and Clinical Issues

verfasst von: Edmond J. Byrnes III, Kieren A. Marr

Erschienen in: Current Infectious Disease Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Over the previous decade, we observed the emergence of the fungal pathogen, Cryptococcus gattii, as a cause of disease in humans and animals in a temperate climate. This outbreak, first documented on Vancouver Island, has since expanded throughout Western North America, with non–travel-associated cases now in British Columbia, Washington, Oregon, and California. Additionally, a secondary outbreak, originating in and still restricted to Oregon, has also occurred. During the past several years, several studies detailing molecular typing, virulence, antifungal susceptibilities, epidemiology, and clinical issues have been published. These studies begin to address the complex dynamics of this novel emergence of a rare and fatal fungus, outline clinical characteristics of human cases, and also opened several new areas that should be explored in the upcoming years.
Literatur
1.
2.
Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004;430:242–9.PubMedCrossRef
3.
Morens DM, Folkers GK, Fauci AS. Emerging infections: a perpetual challenge. Lancet Infect Dis. 2008;8:710–9.PubMedCrossRef
4.
King DA, Peckham C, Waage JK, et al. Epidemiology. Infectious diseases: preparing for the future. Science. 2006;313:1392–3.PubMedCrossRef
5.
•• Galanis E, MacDougall L. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007. Emerg Infect Dis. 2010;16:251–7. This important study documents the epidemiological details of the C. gattii outbreak within British Columbia from the onset in 1999 through 2007. Interestingly, the authors found that although VGIIa predominates (>95% of cases), it does not seem to cause greater illness or death when compared to other strains. More and larger studies will be necessary to determine if clinical outcomes are different based on isolate types.PubMed
6.
Fisher D, Burrow J, Lo D, Currie B. Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomes. Aust N Z J Med. 1993;23:678–82.PubMed
7.
Seaton RA. The management of cryptococcal meningitis in Papua New Guinea. P N G Med J. 1996;39:67–73.PubMed
8.
Kwon-Chung KJ. Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia. 1976;68:821–33.PubMedCrossRef
9.
Kwon-Chung KJ. A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes. Mycologia. 1976;68:943–6.PubMed
10.
Casadevall A, Perfect J. Cryptococcus neoformans. Washington: ASM; 1998.
11.
Findley K, Rodriguez-Carres M, Metin B, et al. Phylogeny and phenotypic characterization of pathogenic Cryptococcus species and closely related saprobic taxa in the Tremellales. Eukaryot Cell. 2009;8:353–61.PubMedCrossRef
12.
Heitman J, Kozel T, Kwon-Chung J, et al. Cryptococcus: from human pathogen to model yeast. Washington: ASM; 2011.
13.
Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–30.PubMedCrossRef
14.
Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res. 2006;6:574–87.PubMedCrossRef
15.
Boekhout T, Theelen B, Diaz M, et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology. 2001;147:891–907.PubMed
16.
Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982;15:535–7.PubMed
17.
Kidd SE, Guo H, Bartlett KH, et al. Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. Eukaryot Cell. 2005;4:1629–38.PubMedCrossRef
18.
Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol. 2001;39:155–68.PubMed
19.
•• Byrnes 3rd EJ, Li W, Lewit Y, et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 2010;6:e1000850. This study uses high-resolution molecular typing to illustrate a clear expansion of the C. gattii outbreak throughout Washington and Oregon. Additionally, virulence of the novel VGIIc genotype is characterized, showing high virulence (similar to VGIIa) in both macrophage and murine models of infection.PubMedCrossRef
20.
Fraser JA, Giles SS, Wenink EC, et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature. 2005;437:1360–4.PubMedCrossRef
21.
Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A. 2004;101:17258–63.PubMedCrossRef
22.
Castanon-Olivares LR, Lopez-Martinez R, Barriga-Angulo G, Rios-Rosas C. Crytococcus neoformans var. gattii in an AIDS patient: first observation in Mexico. J Med Vet Mycol. 1997;35:57–9.PubMedCrossRef
23.
Olivares LR, Martinez KM, Cruz RM, et al.: Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by PCR-fingerprinting. Med Mycol: (2009) 1-9.
24.
Byrnes EJ, 3 rd, Li W, Ren P, et al.: A diverse population of Cryptococcus gattii molecular type VGIII in Southern Californian HIV/AIDS patients. PLoS Pathog Under Review (2011)
25.
Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V. Cryptococcus gattii in AIDS patients, southern California. Emerg Infect Dis. 2005;11:1686–92.PubMed
26.
Kidd SE, Chow Y, Mak S, et al. Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl Environ Microbiol. 2007;73:1433–43.PubMedCrossRef
27.
Byrnes 3rd EJ, Bildfell RJ, Dearing PL, et al. Cryptococcus gattii with bimorphic colony types in a dog in western Oregon: additional evidence for expansion of the Vancouver Island outbreak. J Vet Diagn Invest. 2009;21:133–6.PubMed
28.
Byrnes 3rd EJ, Bildfell RJ, Frank SA, et al. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis. 2009;199:1081–6.PubMedCrossRef
29.
Duncan C, Bartlett KH, Lester S, et al.: Surveillance for Cryptococcus gattii in horses of Vancouver Island, British Columbia, Canada. Med Mycol In Press (2011)
30.
Duncan C, Schwantje H, Stephen C, et al. Cryptococcus gattii in wildlife of Vancouver Island, British Columbia, Canada. J Wildl Dis. 2006;42:175–8.PubMed
31.
Stephen C, Lester S, Black W, et al. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J. 2002;43:792–4.PubMed
32.
Litvintseva AP, Thakur R, Vilgalys R, Mitchell TG. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics. 2006;172:2223–38.PubMedCrossRef
33.
MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis. 2007;13:42–50.PubMedCrossRef
34.
Meyer W, Aanensen DM, Boekhout T, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 2009;47:561–70.PubMedCrossRef
35.
Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998;95:3140–5.PubMedCrossRef
36.
Upton A, Fraser JA, Kidd SE, et al. First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J Clin Microbiol. 2007;45:3086–8.PubMedCrossRef
37.
Iqbal N, Debess EE, Wohrle R, et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii from the Pacific Northwest of the United States. J Clin Microbiol. 2009;48:539–44.PubMedCrossRef
38.
• Ma H, Hagen F, Stekel DJ, et al. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci U S A. 2009;106:12980–5. In this study, Ma et al. show that the VGIIa genotype has a high proliferation rate inside macrophages. They also show that this phenotype correlated to both in vivo virulence and a tubular mitochondrial phenotype. Via microarray analysis, their findings suggest that the VGIIa mitochondrial genome might be implicated in virulence.PubMedCrossRef
39.
West SK, Byrnes EJ, 3 rd , Mostad S, et al.: Emergence of Cryptococcus gattii in the Pacific Northwest United States. Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 25–28, 2008 Oral presentation, Session 179 Abstract M-1849 Page 658 of the Abstract Book. (2008)
40.
•• CDC: Emergence of Cryptococcus gattii—Pacific Northwest, 2004–2010. MMWR Morb Mortal Wkly Rep (2011) 59: 865–868. This report is the first comprehensive public health study of the C. gattii outbreak within the United States. In total, more than 50 human cases are documented. It is also shown that although the mortality rate in Canada is less than 9%, the mortality rate in the United States ranges from 20% to 33%.
41.
• Macdougall L, Fyfe M, Romney M, et al. Risk Factors for Cryptococcus gattii Infection, British Columbia, Canada. Emerg Infect Dis. 2011;17:193–9. This study documents risk factors for C. gattii infection in people diagnosed in British Columbia, Canada. The authors found that receipt of oral corticosteroids, pneumonia, lung conditions, ≥50 years of age, smoking, HIV infection, and history of invasive cancer were all significant factors associated with infection. Although this infection has classically been reported to cause infection in otherwise healthy people, patients with infection in North America have had a multitude of underlying diagnoses.PubMed
42.
Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.PubMedCrossRef
43.
Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30:47–54.PubMedCrossRef
44.
Lane M, McBride J, Archer J. Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis. Neurology. 2004;63:713–4.PubMed
45.
Phillips P, Chapman K, Sharp M, et al. Dexamethasone in Cryptococcus gattii central nervous system infection. Clin Infect Dis. 2009;49:591–5.PubMedCrossRef
46.
Hagen F, Illnait-Zaragozi MT, Bartlett KH, et al.: In vitro antifungal susceptibilities and AFLP genotyping of a worldwide collection of 350 clinical, veterinary and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother (2010).
47.
• Datta K, Bartlett KH, Baer R, et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis. 2009;15:1185–91. This paper highlighted and reviewed the emergence of the outbreak, overviewed previous findings, and recommended future goals. Importantly, this paper was a product of a multidisciplinary and international C. gattii working group of the Pacific Northwest.PubMedCrossRef
48.
Datta K, Bartlett KH, Marr KA: Cryptococcus gattii: Emergence in Western North America: Exploitation of a Novel Ecological Niche. Interdiscip Perspect Infect Dis 2009: 176532.
49.
D’Souza CA, Kronstad JW, Taylor G, et al.: Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. MBio (2011) 2.
Metadaten
Titel
The Outbreak of Cryptococcus gattii in Western North America: Epidemiology and Clinical Issues
verfasst von
Edmond J. Byrnes III
Kieren A. Marr
Publikationsdatum
01.06.2011
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 3/2011
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0181-0

Weitere Artikel der Ausgabe 3/2011

Current Infectious Disease Reports 3/2011 Zur Ausgabe

ReviewPaper

Modern Management of Community-Acquired Pneumonia: Is It Cost-Effective and are Outcomes Acceptable?

ReviewPaper

Clinical Toxinology

ReviewPaper

Chikungunya Virus Infection

ReviewPaper

The Use of Interferon-γ Release Assays for Tuberculosis Screening in International Travelers

ReviewPaper

Update on Necrotizing Mediastinitis: Causes, Approaches to Management, and Outcomes

ReviewPaper

TNF-α Antagonists and Immunization

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise